Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the stroke-risk indication is supported. The remaining pharmacology/mechanism, ulcer-mucus/COX-2 claims, PPI/food advice, monitoring for specific bleeding signs, and “abrupt stopping” cardiovascular risk are not supported by the provided label excerpts and conflict with the label’s focus on bleeding risk and specific contraindications/precautions.
Category Scores
Accurate Statements
The drug is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain (TIA) or completed ischemic stroke due to thrombosis.
Indications and Usage: “...indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.”
Unsupported Statements
Aspirin works by inhibiting the production of prostaglandins.
No mechanism-of-action/prostaglandin-production statement provided in the supplied label excerpts.
Aspirin suppression of the protective mucus layer in the stomach makes the stomach more susceptible to acid damage and ulcer formation.
The provided label excerpts do not state this mucus/acid-damage mechanism.
Long-term aspirin use is associated with an increased risk of developing stomach ulcers in patients with a history of gastrointestinal bleeding.
The provided label excerpts mention GI bleeding risk and avoiding aspirin in patients with a history of active peptic ulcer disease, but do not support a claim specifically about long-term use + history of GI bleeding causing ulcers.
Aspirin inhibits the activity of cyclooxygenase-2 (COX-2) enzymes.
No COX-2-specific mechanism provided in the supplied label excerpts.
COX-2 enzymes are involved in the production of mucus and bicarbonate that protect the stomach lining from acid damage.
Not supported by the supplied label excerpts.
By inhibiting COX-2 enzymes, aspirin can disrupt the protective mechanism and lead to an increased risk of stomach ulcers.
Not supported by the supplied label excerpts (and relies on prior unsupported COX-2/mucus-bicarbonate mechanism).
A proton pump inhibitor (PPI) can help reduce stomach acid production and promote healing of existing ulcers in patients taking aspirin.
No PPI-related advice or recommendation appears in the supplied label excerpts.
Taking aspirin with food can help buffer stomach acid and reduce the risk of ulcers.
The supplied label excerpt states the product can be administered with or without food, but does not state that taking with food reduces ulcer risk.
Patients taking aspirin should monitor for signs of bleeding such as black tarry stools or vomiting blood.
The supplied label excerpts do not provide this monitoring guidance for specific stool/vomiting signs.
Long-term aspirin use can increase the risk of stomach ulcers, particularly in patients with a history of gastrointestinal bleeding.
The supplied label excerpts emphasize bleeding risk and advise avoiding aspirin in patients with a history of active peptic ulcer disease, but do not support this specific long-term + GI-bleeding-history ulcer framing.
Stopping aspirin abruptly can increase the risk of cardiovascular events.
No statement about stopping/abrupt discontinuation risk is provided in the supplied label excerpts.
Aspirin suppression of the protective mucus layer in the stomach makes the stomach more susceptible to acid damage and ulcer formation.
Not supported by the supplied label excerpts.
Contradictions
Low
AI Statement
Taking aspirin with food can help buffer stomach acid and reduce the risk of ulcers.
Label Reference
Dosage and Administration: “...can be administered with or without food.” (No claim that food reduces ulcer risk.)
Important Omissions
FDA-approved indications beyond the stroke-risk claim (including specific patient population: TIA or completed ischemic stroke due to thrombosis) are not addressed by the other claims; however this is only an omission relative to the user’s set of claims rather than the label response overall.
Importance:
Low
Key label warnings/precautions such as increased risk of bleeding, avoidance in patients with a history of active peptic ulcer disease, contraindications (hypersensitivity/NSAID allergy/aspirin-exacerbated respiratory disease; Reye syndrome in children/teens with viral infections), and specific administration instructions (swallow whole; not interchangeable with components) are not included in the provided claim set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce unsupported mechanism-based ulcer risk explanations and specific management/monitoring guidance (PPI use, food buffering, specific bleeding sign monitoring, abrupt discontinuation cardiovascular risk) that are not supported by the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most non-indication claims (mechanism via prostaglandins/COX-2, ulcer-mucus/acid mechanism, PPI/food guidance, specific bleeding-sign monitoring, and abrupt stopping risk) are not supported by the supplied FDA label excerpts and some statements are framed as if label-supported.
Suggested Improvement
Restrict statements to provided label content: indication (stroke-risk reduction in TIA/completed ischemic stroke due to thrombosis), administration (swallow whole; with or without food; not interchangeable), and label-supported warnings (increased bleeding risk; avoid in history of active peptic ulcer disease; counsel about bleeding risk with chronic heavy alcohol use). Avoid introducing COX-2/prostaglandin/ulcer-mucus mechanisms, PPI recommendations, and specific discontinuation/monitoring claims unless present verbatim in the label excerpts.